A PYMNTS Company

Pfizer and Ranbaxy sued for delay of Lipitor generic

By  |  December 20, 2012

The AFL-AGC Building Trades Welfare plan alleges that Pfizer and Ranbaxy delayed a generic version of Lipitor for 20 months. The plan has brought a proposed class-action lawsuit in U.S. District Court, Southern District of New York (Manhattan). Plaintiffs claim that Ranbaxy, the manufacturer of the generic, entered into an anticompetitive scheme with Pfizer, whose patent for Lipitor expired on March 24, 2010.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Source: Bloomberg

     

    Related content: Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements (Anne Layne-Farrar, Compass Lexecon)